相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Therapeutic Sequencing in ALK(+) NSCLC
Mei Elsayed et al.
PHARMACEUTICALS (2021)
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer
Nikolaus Magios et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
T. Mok et al.
ANNALS OF ONCOLOGY (2020)
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA
Steffen Dietz et al.
EBIOMEDICINE (2020)
Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
David M. Waterhouse et al.
DRUGS-REAL WORLD OUTCOMES (2020)
TPX-0131: A next generation macrocyclic ALK inhibitor that overcomes ALK resistant mutations refractory to current approved ALK inhibitors
J. Jean Cui et al.
CANCER RESEARCH (2020)
Treatment sequencing in oncology: balancing clinical trial and real-world evidence Foreword
Orazio Caffo
FUTURE ONCOLOGY (2019)
1538PReal-world implementation of sequential targeted therapies for EGFR-mutated NSCLC
P Christopoulos et al.
ANNALS OF ONCOLOGY (2019)
Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases
Anna-Lena Volckmar et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival
Petros Christopoulos et al.
CANCERS (2019)
A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications
Anna-Lena Volckmar et al.
GENES CHROMOSOMES & CANCER (2018)
Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer
Caroline E. McCoach et al.
CLINICAL CANCER RESEARCH (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Risk of not receiving 2nd line therapy is high in EGFR mt plus pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt plus pts
Julia Roeper et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J. Solomon et al.
LANCET ONCOLOGY (2018)
Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer
Szu-Chun Yang et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA
Ibiayi Dagogo-Jack et al.
JCO PRECISION ONCOLOGY (2018)
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
Ethan Basch et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Sequential Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study
Kentaro Ito et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Targeting ALK: Precision Medicine Takes on Drug Resistance
Jessica J. Lin et al.
CANCER DISCOVERY (2017)
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
Michael Duruisseaux et al.
ONCOTARGET (2017)
Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged NoneSmall-Cell Lung Cancer: A Retrospective Analysis
Tetsuhiko Asao et al.
CLINICAL LUNG CANCER (2017)
H08Sequential strategy with ALK-TKIs for ALK-positive advanced NSCLC: results of a multicenter analysis
M.F. Currà et al.
ANNALS OF ONCOLOGY (2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor et al.
CANCER DISCOVERY (2016)
Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?
Adrian G. Sacher et al.
CANCER (2015)
The 2015 World Health Organization Classification of Lung Tumors Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Predictors and Impact of Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer in the United States Real-World Considerations for Maintenance Therapy
David E. Gerber et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Prevalence and effectiveness of first-, second-, and third-line systemic therapy in a cohort of unselected patients with advanced non-small cell lung cancer
V. Zietemann et al.
LUNG CANCER (2011)
Every-day clinical practice in patients with advanced non-small-cell lung cancer
V. Zietemann et al.
LUNG CANCER (2010)
分享论文
